Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.